Trial Profile

A long term placebo controlled study assessing Edaravone

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 03 Jun 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Edaravone (Primary)
Indications Amyotrophic lateral sclerosis
Focus Therapeutic Use

Most Recent Events

03 Jun 2019 New trial record
30 May 2019 According to a Mitsubishi Tanabe Pharma Corporation, Mitsubishi Tanabe Pharma Corporation that this additional study of atleast 12 months duration would be required to obtain the data necessary for the regulatory approval in the EU. The company believes that the efficacy and safety of edaravone has been demonstrated and this study is unwarranted.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com